Stock Movers PNC Financial Rises; JB Hunt Slides After Revenue Miss; Novo Nordisk Extends Gains
Jan 16, 2026
PNC Financial shares soar with strong revenue projections and a better-than-expected quarter. In contrast, JB Hunt sees a drop in stock prices following a revenue miss, reflecting ongoing challenges in the trucking industry. Meanwhile, Novo Nordisk gains momentum after the UK approves a higher dose of Wegovy for obesity treatment, delighting analysts. Additionally, memory-chip companies SanDisk and Micron benefit from rising prices, showcasing a notable performance in the S&P 500.
AI Snips
Chapters
Transcript
Episode notes
PNC Shows Middle-Market Momentum
- PNC beat Q4 estimates with $6.1 billion revenue and $4.88 EPS driving shares higher in pre-market trading.
- Revenue strength came from deal-making and financing for middle-market (mid-sized) businesses expanding activity.
Freight Slump Hits J.B. Hunt
- J.B. Hunt's shares fell after Q3 sales of $3.1 billion missed estimates amid weaker long-haul shipments.
- The company offset softness by cutting costs and beating on earnings, but industry demand remains soft with oversupply of trucks.
Wegovy Dose Approval Boosts Novo
- Novo Nordisk ADR popped after the UK approved a higher Wegovy dose for obesity and analysts raised sales expectations.
- Positive news for Novo pressured Eli Lilly a bit as investors reassess competitive dynamics in obesity treatments.